The U.S. Food and Drug Administration (FDA), part of the U.S. Department of Health and Human Services (HHS), has announced the Rare Disease Framework Initiative to reshape the development and regulatory review of drugs and biologics for rare diseases. The initiative, detailed in a new white paper, aims to establish an optimized, fit-for-purpose framework that accounts for the specific challenges associated with developing treatments for rare conditions.
The proposed approach will consider the characteristics of individual diseases, patient needs, product types and the evidence that can realistically be generated from small patient populations. Through the Rare Disease Framework Initiative, the FDA intends to develop a regulatory approach that better reflects the circumstances of rare disease drug development while addressing the needs of patients and families. To gather feedback from patients, disease advocates, industry representatives and other stakeholders, the agency will hold a public meeting on 28th October 2026 at the FDA’s White Oak campus. The Reagan-Udall Foundation for the FDA will facilitate the meeting.
FDA Highlights Patient Needs and Regulatory Flexibility
“Americans with rare diseases cannot afford a regulatory system that treats every condition the same,” said HHS Secretary Robert F. Kennedy, Jr.
“Under President Trump, FDA is rethinking rare disease drug development by putting patients at the center and matching regulatory requirements to the realities of small patient populations. We will remove unnecessary barriers, embrace cutting-edge science, and accelerate promising treatments while upholding FDA’s rigorous standards,” he added.
“Patients and families living with rare diseases have few or no approved treatment options, and the burden of uncertainty can extend across every part of their lives,” said Acting FDA Commissioner Kyle Diamantas, J.D.
Six Priorities for Improving Rare Disease Treatment Development
The FDA has previously introduced regulatory flexibility and targeted programs to encourage innovation in developing drugs and biologics for rare diseases, resulting in meaningful advances for patients and families. However, with only 5% or so of rare conditions having an FDA-approved treatment, the agency recognizes the need for additional measures to accelerate the availability of safe and effective therapies. Under the Rare Disease Framework Initiative, the FDA has identified six priorities:
- Providing greater clarity, consistency and predictability in regulatory decisions through tailored guidance and transparent communication
- Incorporating the patient’s voice early and at clearly defined milestones throughout drug development and review
- Making greater use of external expertise to customize regulatory assessments
- Developing shared resources, robust training and institutional knowledge for rare disease drug development and review
- Adopting risk-based approaches, particularly for chemistry, manufacturing, and controls review and pre-approval inspections
- Promoting cutting-edge science, novel methods and innovative statistical approaches in rare disease drug development
The initiative is led by the FDA’s Rare Disease Innovation Hub in partnership with the Office of the Commissioner, the Center for Biologics Evaluation and Research, and the Center for Drug Evaluation and Research.
